The global liquid biopsy market size is calculated at USD 7.05 billion in 2025 and is forecasted to reach around USD 22.69 billion by 2034, accelerating at a CAGR of 13.91% from 2025 to 2034. The North America liquid biopsy market size surpassed USD 2.81 billion in 2024 and is expanding at a CAGR of 13.95% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
7.1. Liquid Biopsy Market, by Technology
7.1.1. NGS
7.1.1.1. Market Revenue and Forecast
7.1.2. PCR
7.1.2.1. Market Revenue and Forecast
7.1.3. FISH
7.1.3.1. Market Revenue and Forecast
7.1.4. Other
7.1.4.1. Market Revenue and Forecast
8.1. Liquid Biopsy Market, by Usage
8.1.1. RUO
8.1.1.1. Market Revenue and Forecast
8.1.2. Clinical
8.1.2.1. Market Revenue and Forecast
9.1. Liquid Biopsy Market, by Types of Sample
9.1.1. Blood
9.1.1.1. Market Revenue and Forecast
9.1.2. Urine
9.1.2.1. Market Revenue and Forecast
9.1.3. Saliva
9.1.3.1. Market Revenue and Forecast
9.1.4. CerebroSpinal Fluid
9.1.4.1. Market Revenue and Forecast
10.1. Liquid Biopsy Market, by Circulating Biomarker
10.1.1. Circulating Tumor Cells
10.1.1.1. Market Revenue and Forecast
10.1.2. Cell-free DNA
10.1.2.1. Market Revenue and Forecast
10.1.3. Circulating Cell-Free RNA
10.1.3.1. Market Revenue and Forecast
10.1.4. Exosomes and Extracellular Vesicles
10.1.4.1. Market Revenue and Forecast
10.1.5. Others
10.1.5.1. Market Revenue and Forecast
11.1. Liquid Biopsy Market, by Products
11.1.1. Test/Services
11.1.1.1. Market Revenue and Forecast
11.1.2. Kits and Consumable
11.1.2.1. Market Revenue and Forecast
11.1.3. Instruments
11.1.3.1. Market Revenue and Forecast
12.1. Liquid Biopsy Market, by Indication Type
12.1.1. Lung Cancer
12.1.1.1. Market Revenue and Forecast
12.1.2. Breast Cancer
12.1.2.1. Market Revenue and Forecast
12.1.3. Prostate Cancer
12.1.3.1. Market Revenue and Forecast
12.1.4. Colorectal Cancer
12.1.4.1. Market Revenue and Forecast
12.1.5. Melanoma
12.1.5.1. Market Revenue and Forecast
12.1.6. Other cancers
12.1.6.1. Market Revenue and Forecast
12.1.7. Non-Oncology Disorders
12.1.7.1. Market Revenue and Forecast
13.1. Liquid Biopsy Market, by Clinical Application
13.1.1. Treatment Monitoring
13.1.1.1. Market Revenue and Forecast
13.1.2. Prognosis and Recurrence Monitoring
13.1.2.1. Market Revenue and Forecast
13.1.3. Treatment Selection
13.1.3.1. Market Revenue and Forecast
13.1.4. Diagnosis and Screening
13.1.4.1. Market Revenue and Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Technology
14.1.2. Market Revenue and Forecast, by Usage
14.1.3. Market Revenue and Forecast, by Types of Sample
14.1.4. Market Revenue and Forecast, by Circulating Biomarker
14.1.5. Market Revenue and Forecast, by Products
14.1.6. Market Revenue and Forecast, by Clinical Application
14.1.7. Market Revenue and Forecast, by Indication Type
14.1.8. U.S.
14.1.8.1. Market Revenue and Forecast, by Technology
14.1.8.2. Market Revenue and Forecast, by Usage
14.1.8.3. Market Revenue and Forecast, by Types of Sample
14.1.8.4. Market Revenue and Forecast, by Circulating Biomarker
14.1.8.5. Market Revenue and Forecast, by Products
14.1.8.6. Market Revenue and Forecast, by Clinical Application
14.1.8.7. Market Revenue and Forecast, by Indication Type
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Technology
14.1.9.2. Market Revenue and Forecast, by Usage
14.1.9.3. Market Revenue and Forecast, by Types of Sample
14.1.9.4. Market Revenue and Forecast, by Circulating Biomarker
14.1.9.5. Market Revenue and Forecast, by Products
14.1.9.6. Market Revenue and Forecast, by Clinical Application
14.1.9.7. Market Revenue and Forecast, by Indication Type
14.2. Europe
14.2.1. Market Revenue and Forecast, by Technology
14.2.2. Market Revenue and Forecast, by Usage
14.2.3. Market Revenue and Forecast, by Types of Sample
14.2.4. Market Revenue and Forecast, by Circulating Biomarker
14.2.5. Market Revenue and Forecast, by Products
14.2.6. Market Revenue and Forecast, by Clinical Application
14.2.7. Market Revenue and Forecast, by Indication Type
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Technology
14.2.8.2. Market Revenue and Forecast, by Usage
14.2.8.3. Market Revenue and Forecast, by Types of Sample
14.2.8.4. Market Revenue and Forecast, by Circulating Biomarker
14.2.8.5. Market Revenue and Forecast, by Products
14.2.8.6. Market Revenue and Forecast, by Clinical Application
14.2.8.7. Market Revenue and Forecast, by Indication Type
14.2.9. Germany
14.2.9.1. Market Revenue and Forecast, by Technology
14.2.9.2. Market Revenue and Forecast, by Usage
14.2.9.3. Market Revenue and Forecast, by Types of Sample
14.2.9.4. Market Revenue and Forecast, by Circulating Biomarker
14.2.9.5. Market Revenue and Forecast, by Products
14.2.9.6. Market Revenue and Forecast, by Clinical Application
14.2.9.7. Market Revenue and Forecast, by Indication Type
14.2.10. France
14.2.10.1. Market Revenue and Forecast, by Technology
14.2.10.2. Market Revenue and Forecast, by Usage
14.2.10.3. Market Revenue and Forecast, by Types of Sample
14.2.10.4. Market Revenue and Forecast, by Circulating Biomarker
14.2.10.5. Market Revenue and Forecast, by Products
14.2.10.6. Market Revenue and Forecast, by Clinical Application
14.2.10.7. Market Revenue and Forecast, by Indication Type
14.2.11. Rest of Europe
14.2.11.1. Market Revenue and Forecast, by Technology
14.2.11.2. Market Revenue and Forecast, by Usage
14.2.11.3. Market Revenue and Forecast, by Types of Sample
14.2.11.4. Market Revenue and Forecast, by Circulating Biomarker
14.2.11.5. Market Revenue and Forecast, by Products
14.2.11.6. Market Revenue and Forecast, by Clinical Application
14.2.11.7. Market Revenue and Forecast, by Indication Type
14.3. APAC
14.3.1. Market Revenue and Forecast, by Technology
14.3.2. Market Revenue and Forecast, by Usage
14.3.3. Market Revenue and Forecast, by Types of Sample
14.3.4. Market Revenue and Forecast, by Circulating Biomarker
14.3.5. Market Revenue and Forecast, by Products
14.3.6. Market Revenue and Forecast, by Clinical Application
14.3.7. Market Revenue and Forecast, by Indication Type
14.3.8. India
14.3.8.1. Market Revenue and Forecast, by Technology
14.3.8.2. Market Revenue and Forecast, by Usage
14.3.8.3. Market Revenue and Forecast, by Types of Sample
14.3.8.4. Market Revenue and Forecast, by Circulating Biomarker
14.3.8.5. Market Revenue and Forecast, by Products
14.3.8.6. Market Revenue and Forecast, by Clinical Application
14.3.8.7. Market Revenue and Forecast, by Indication Type
14.3.9. China
14.3.9.1. Market Revenue and Forecast, by Technology
14.3.9.2. Market Revenue and Forecast, by Usage
14.3.9.3. Market Revenue and Forecast, by Types of Sample
14.3.9.4. Market Revenue and Forecast, by Circulating Biomarker
14.3.9.5. Market Revenue and Forecast, by Products
14.3.9.6. Market Revenue and Forecast, by Clinical Application
14.3.9.7. Market Revenue and Forecast, by Indication Type
14.3.10. Japan
14.3.10.1. Market Revenue and Forecast, by Technology
14.3.10.2. Market Revenue and Forecast, by Usage
14.3.10.3. Market Revenue and Forecast, by Types of Sample
14.3.10.4. Market Revenue and Forecast, by Circulating Biomarker
14.3.10.5. Market Revenue and Forecast, by Products
14.3.10.6. Market Revenue and Forecast, by Clinical Application
14.3.10.7. Market Revenue and Forecast, by Indication Type
14.3.11. Rest of APAC
14.3.11.1. Market Revenue and Forecast, by Technology
14.3.11.2. Market Revenue and Forecast, by Usage
14.3.11.3. Market Revenue and Forecast, by Types of Sample
14.3.11.4. Market Revenue and Forecast, by Circulating Biomarker
14.3.11.5. Market Revenue and Forecast, by Products
14.3.11.6. Market Revenue and Forecast, by Clinical Application
14.3.11.7. Market Revenue and Forecast, by Indication Type
14.4. MEA
14.4.1. Market Revenue and Forecast, by Technology
14.4.2. Market Revenue and Forecast, by Usage
14.4.3. Market Revenue and Forecast, by Types of Sample
14.4.4. Market Revenue and Forecast, by Circulating Biomarker
14.4.5. Market Revenue and Forecast, by Products
14.4.6. Market Revenue and Forecast, by Clinical Application
14.4.7. Market Revenue and Forecast, by Indication Type
14.4.8. GCC
14.4.8.1. Market Revenue and Forecast, by Technology
14.4.8.2. Market Revenue and Forecast, by Usage
14.4.8.3. Market Revenue and Forecast, by Types of Sample
14.4.8.4. Market Revenue and Forecast, by Circulating Biomarker
14.4.8.5. Market Revenue and Forecast, by Products
14.4.8.6. Market Revenue and Forecast, by Clinical Application
14.4.8.7. Market Revenue and Forecast, by Indication Type
14.4.9. North Africa
14.4.9.1. Market Revenue and Forecast, by Technology
14.4.9.2. Market Revenue and Forecast, by Usage
14.4.9.3. Market Revenue and Forecast, by Types of Sample
14.4.9.4. Market Revenue and Forecast, by Circulating Biomarker
14.4.9.5. Market Revenue and Forecast, by Products
14.4.9.6. Market Revenue and Forecast, by Clinical Application
14.4.9.7. Market Revenue and Forecast, by Indication Type
14.4.10. South Africa
14.4.10.1. Market Revenue and Forecast, by Technology
14.4.10.2. Market Revenue and Forecast, by Usage
14.4.10.3. Market Revenue and Forecast, by Types of Sample
14.4.10.4. Market Revenue and Forecast, by Circulating Biomarker
14.4.10.5. Market Revenue and Forecast, by Products
14.4.10.6. Market Revenue and Forecast, by Clinical Application
14.4.10.7. Market Revenue and Forecast, by Indication Type
14.4.11. Rest of MEA
14.4.11.1. Market Revenue and Forecast, by Technology
14.4.11.2. Market Revenue and Forecast, by Usage
14.4.11.3. Market Revenue and Forecast, by Types of Sample
14.4.11.4. Market Revenue and Forecast, by Circulating Biomarker
14.4.11.5. Market Revenue and Forecast, by Products
14.4.11.6. Market Revenue and Forecast, by Clinical Application
14.4.11.7. Market Revenue and Forecast, by Indication Type
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Technology
14.5.2. Market Revenue and Forecast, by Usage
14.5.3. Market Revenue and Forecast, by Types of Sample
14.5.4. Market Revenue and Forecast, by Circulating Biomarker
14.5.5. Market Revenue and Forecast, by Products
14.5.6. Market Revenue and Forecast, by Clinical Application
14.5.7. Market Revenue and Forecast, by Indication Type
14.5.8. Brazil
14.5.8.1. Market Revenue and Forecast, by Technology
14.5.8.2. Market Revenue and Forecast, by Usage
14.5.8.3. Market Revenue and Forecast, by Types of Sample
14.5.8.4. Market Revenue and Forecast, by Circulating Biomarker
14.5.8.5. Market Revenue and Forecast, by Products
14.5.8.6. Market Revenue and Forecast, by Clinical Application
14.5.8.7. Market Revenue and Forecast, by Indication Type
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Technology
14.5.9.2. Market Revenue and Forecast, by Usage
14.5.9.3. Market Revenue and Forecast, by Types of Sample
14.5.9.4. Market Revenue and Forecast, by Circulating Biomarker
14.5.9.5. Market Revenue and Forecast, by Products
14.5.9.6. Market Revenue and Forecast, by Clinical Application
14.5.9.7. Market Revenue and Forecast, by Indication Type
15.1. Bio-Rad Laboratories
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Biocept Inc.
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Guardant Health
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Illumina, Inc.
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. F. Hoffmann-La Roche Ltd.
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Johnson & Johnson
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Laboratory Corporation of America Holdings
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. MDxHealth SA
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. QIAGEN N.V
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Thermo Fisher Scientific Inc.
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample